ArticleScientific reports2022

Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.

Chia-Han Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.